



PRELIMINARY TIMETABLE AS OF 21 May 2017
 *SUBJECT TO CHANGE

THURSDAY, 1 JUNE 2017

Time	GIRALDA I-II
13:30-15:30	Best Abstract Presentations
15:30-17:30	Session 1: NAFLD the Big Picture Chair: Ramon Bataller 20 mins Histological Definition of NAFLD Pierre Bedossa (France) 20 mins Clinical-laboratory Assessment of NAFLD Puneet Puri (USA) 20 mins Imaging and Elastography-based Approaches Laurent Castera (France) 20 mins Best Practices in Disease Assessment in Daily Care Mary Rinella (USA) 15 mins Panel
17:30-18:00	Coffee Break, Exhibition & Poster Viewing

18:00-19:30	<p>Session 2: Recognizing NAFLD in Your Practice Chair: Khurram Nasir and Laurent Castera</p>
25 mins	<p>Why Should You Care about NAFLD? Quentin M. Anstee (UK)</p>
25 mins	<p>How Common is NASH in your Diabetes Clinic? Elisabetta Bugianesi (Italy)</p>
25 mins	<p>How Common is NASH in Primary Care? Mazen Nouredin (USA)</p>
15 mins	<p>Panel Discussion</p>
19:30	<p>WELCOME & RECEPTION</p> <p>Welcome & Introduction from Organising Committee Arun J. Sanyal (USA); Rifaat Safadi (Israel); Quentin M. Anstee (UK) Followed by Networking Reception</p>

FRIDAY, 2 JUNE 2017

NAFLD AS PART OF A MULTI DISCIPLINARY DISEASE

Time	GIRALDA I-II
08:00-10:00	Session 3: NASH and Cardiovascular Disease Chair: Jerry L. Nadler and Puneet Puri
25 mins	NAFLD and Cardiovascular Disease- Weighing the Evidence Critically <i>Khurram Nasir (USA)</i>
25 mins	Atherogenic Dyslipidemia and NAFLD <i>Arun J. Sanyal (USA)</i>
25 mins	Cardiomyopathy Associated with NAFLD <i>Mohammed Siddiqui (USA)</i>
25 mins	Coagulation and NAFLD <i>J.A.(Ton) Lisman (Netherlands)</i>
20 mins	Panel Discussion – All including chairs
10:00-10:30	Coffee Break, Exhibition & e-Poster Viewing Best Poster Presentations in E-Poster Area
10:30-12:30	Session 4: Diabetes and NAFLD Chair: Mary Rinella
20 mins	Diabetes and NAFLD - is it One Disease Two Target Organs <i>Jerry L. Nadler (USA)</i>
20 mins	Towards Diabetes Cure-implications for NAFLD <i>TBC</i>
20 mins	Entero-hepatic Lipid-signaling in the Metabolic Syndrome and NAFLD <i>Bart Staels (France)</i>
40 mins	The Great Debate: Will NAFLD Become an Irrelevant Clinical Entity with Tight Glycemic Control <i>Hannele Yki-Järvinen, Finland - YES</i> <i>María Teresa Arias-Loste, Spain - NO</i>
20 mins	Questions and Panel Discussion
12:30-14:00	Break, Exhibition & e-Poster Viewing

14:00-15:30	<p>Session 5: Drug Safety in a Primary Care Setting Chair: J.A.(Ton) Lisman and María Teresa Arias-Loste</p> <p>25 mins NAFLD as a manifestation of DILI in HIV-infected population <i>Lawrence Serfaty (France)</i></p> <p>25 mins Challenges in Assessment of DILI in Obese Diabetic Individuals <i>Raul J. Andrade (Spain)</i></p> <p>25 mins Drug Induced Liver Injury & NAFLD - Do's and Don'ts of Medical Therapy <i>Arie Regev (USA)</i></p> <p>15 mins Audience questions & responses by speakers</p>
15:30-16:00	Coffee Break, Exhibition & e-Poster Viewing
16:00-17:30	<p>Session 6: NASH in Pediatric Practice Chair: Raul J. Andrade</p> <p>25 mins Is NAFLD in Children the Same Disease as in Adults? <i>Valerio Nobili (Italy)</i></p> <p>25 mins Perspectives on NAFLD from a Pediatric Endocrinology Clinic <i>Sonia Caprio (USA)</i></p> <p>25 mins The Trans-Atlantic Pediatric NASH-TARGET Study <i>Miriam Vos (USA)</i></p> <p>15 mins Panel Discussion (Best practices)</p>

SATURDAY, 3 JUNE 2017

NAFLD THE LIVER DISEASE

Time	GIRALDA I-II
<p>08:00-09:30</p> <p>20 mins</p> <p>20 mins</p> <p>40 mins</p> <p>10 mins</p>	<p>Session 7: Liver-related Outcomes in NAFLD Chair: Mohammed Siddiqui and Pierre Bedossa</p> <p>NAFLD and liver cancer Mazen Noureddin (USA)</p> <p>The Bidirectional Evolution of NAFLD Arun J. Sanyal (USA)</p> <p>The GREAT DEBATE- Is it Time to Drop Liver Histology as the Anchor for Assessment of NAFLD Evolution? Yes- Lawrence Castera (France) No- Pierre Bedossa (France)</p> <p>Audience questions to both speakers</p>
<p>09:30-10:00</p>	<p style="text-align: center;">Coffee Break, Exhibition & e-Poster Viewing</p>
<p>10:00-11:30</p> <p>15 mins</p> <p>15 mins</p> <p>15 mins</p> <p>10 mins</p> <p>10 mins</p> <p>10 mins</p> <p>15 mins</p>	<p>Session 8: The NASH Target – Allocation of High Risk Populations Chair: Manuel Romero-Gomez and Franz Martin-Bermudo</p> <p>Screening diabetic clinics Mariana Tomé (Spain)</p> <p>What should the Diabetologist do with his NASH patient Antonio J. Martínez (Spain)</p> <p>NAFLD and liver transplant Rifaat Safadi (Israel)</p> <p>Round Table on NASH REGISTRIES</p> <ul style="list-style-type: none"> - Spanish Registry of NAFLD/NASH (HepMet) (Manuel Romero-Gomez) - European Registry (Quentin Anstee) - CRN The American Registry (Arun Sanyal) <p>Discussion</p>

11:30-12:30	<p>Difficult Cases Session Chairs: Manuel Romero-Gomez and Shira Zelber-Sagi</p> <p>Clinical Case 1: Non-invasive diagnosis of NASH-fibrosis. Aida Ortega, Hospital Virgen de la Victoria, Málaga, Spain. Clinical Case 2: Management of NASH-fibrosis. Salvador Agustín, Hospital Vall d’hebron, Barcelona, Spain. Clinical case 3: Assessment of cardiovascular risk in NASH patients. Nieves Romero, Spain.</p>
12:30-13:30	<p>Break, Exhibition & e-Poster Viewing</p>
<p>13:30-15:30</p> <p>25 mins</p> <p>25 mins</p> <p>25 mins</p> <p>25 mins</p> <p>20 mins</p>	<p>Session 9: What to do When You Find the Disease – Behavior Modification Chair: Arie Regev</p> <p>Managing the Low Risk Patient...Providing Practical Advice Regarding Diet and Exercise – Hepatologist Perspective Manuel Romero Gomez (Spain)</p> <p>Managing the Low Risk Patient...Providing Practical Advice Regarding Diet and Exercise – Nutritionist Perspective Shira Zelber-Sagi (Israel)</p> <p>Food Addiction, Impulsivity and Eating Disorders in Patients with NAFLD Gerry Moeller, USA</p> <p>Alcohol Consumption in the Obese Diabetic Subject- How Much or How Little Ramon Bataller, USA</p> <p>Panel Discussion</p>
15:30-16:00	<p>Coffee Break, Exhibition & e-Poster Viewing</p>
<p>16:00-17:30</p> <p>20 mins</p> <p>20 mins</p> <p>20 mins</p> <p>20 mins</p>	<p>Session 10: Therapeutic Landscape for NASH Chair: Gerry Moeller and Mazen Nouredin</p> <p>Current Compounds in Pivotal Trials Vlad Ratziu (France)</p> <p>Targets Under Evaluation in Early Phase Trials Quentin M. Anstee (UK)</p> <p>Drugs You Can Use in Your Office Today Arun Sanyal (USA)</p> <p>Bariatric Surgery-What is its Role Rifaat Safadi (Israel)</p>

10 mins	Panel Discussion
17:30-17:45	Closing Remarks